Salvage therapy for locally recurrent prostate cancer after radiation

Canadian Journal of Urology

Volumn 19, Issue 6, 2012, Pages 6534-6541

  Marcus, David M ^a,b   Canter, Daniel J ^a,b   Jani, Ashesh B ^a,b   Dobbs, Ryan W ^a   Schuster, David M ^a   Carthon, Bradley C ^b   Rossi, Peter J ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Brachytherapy; Cryotherapy; Prostatectomy; Prostatic neoplasms; Radiotherapy; Salvage therapy

Indexed keywords

AGED; BRACHYTHERAPY; CRYOSURGERY; ELECTROMAGNETIC RADIATION; HUMAN; IMAGE GUIDED RADIOTHERAPY; IMMUNOHISTOCHEMISTRY; LIFESTYLE; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; NEEDLE BIOPSY; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; PROSTATECTOMY; RADIATION DOSE; REVIEW; SALVAGE THERAPY; SURVIVAL; TREATMENT OUTCOME; TUMOR INVASION; TUMOR RECURRENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; BRACHYTHERAPY; CRYOSURGERY; ELECTROMAGNETIC RADIATION; HUMANS; IMMUNOHISTOCHEMISTRY; LIFE STYLE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RADIOTHERAPY, IMAGE-GUIDED; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84878426994     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61(4):212-236.
2. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280(11):969-974.
3. Mohler J, Bahnson RR, Boston B et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010;8(2):162-200.
4. Zietman AL, DeSilvio ML, Slater JD et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294(10):1233-1239.
5. Kuban DA, Tucker SL, Dong L et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70(1):67-74.
6. Kuban DA, Levy LB, Cheung MR et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys 2011;79(5):1310-1317.
7. Kuban DA, Levy LB, Potters L et al. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2006;65(5):1487-1493.
8. Kuban DA, Thames HD, Shipley WU. Defining recurrence after radiation for prostate cancer. J Urol 2005;173(6):1871-1878.
9. Roach M, 3rd, Hanks G, Thames H Jr et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65(4):965-974.
10. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997;37(5): 1035-1041.
11. Zelefsky MJ, Ben-Porat L, Scher HI et al. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol 2005;23(4):826-831.
12. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002;20(23):4567-4573.
13. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003; 95(18):1376-1383.
14. Albertsen PC, Hanley JA, Penson DF, Fine J. Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol 2004;171(6 Pt 1):2221-2225.
15. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591-1597.
16. Jones CU, Hunt D, McGowan DG et al. Radiotherapy and shortterm androgen deprivation for localized prostate cancer. N Engl J Med 2011;365(2):107-118.
17. Crook JM, Perry GA, Robertson S, Esche BA. Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology 1995;45(4):624-631; discussion 631-622.
18. Kundra V, Silverman PM, Matin SF, Choi H. Imaging in oncology from the University of Texas M. D. Anderson Cancer Center: diagnosis, staging, and surveillance of prostate cancer. AJR Am J Roentgenol 2007;189(4):830-844.
19. KelloffGJ, Choyke P, Coffey DS. Challenges in clinical prostate cancer: role of imaging. AJR Am J Roentgenol 2009;192(6):1455-1470.
20. Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med 2008;49(1):68-78.
21. Fowler JE Jr, Brooks J, Pandey P, Seaver LE. Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy. J Urol 1995;153(3 Pt 2):1011-1014.
22. Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004;34(4):274-292.
23. Brassell SA, Rosner IL, McLeod DG. Update on magnetic resonance imaging, ProstaScint, and novel imaging in prostate cancer. Curr Opin Urol 2005;15(3):163-166.
24. Sartor O, McLeod D. Indium-111-capromab pendetide scans: an important test relevant to clinical decision making. Urology 2001; 57(3):399-401.
25. Lange PH. PROSTASCINT scan for staging prostate cancer. Urology 2001;57(3):402-406.
26. Seltzer MA, Barbaric Z, Belldegrun A et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 1999;162(4): 1322-1328.
27. Choo R. Salvage radiotherapy for patients with PSA relapse following radical prostatectomy: issues and challenges. Cancer Res Treat 2010;42(1):1-11.
28. Beresford MJ, Gillatt D, Benson RJ, Ajithkumar T. A systematic review of the role of imaging before salvage radiotherapy for postprostatectomy biochemical recurrence. Clin Oncol (R Coll Radiol) 2010;22(1):46-55.
29. Schuster DM, Savir-Baruch B, Nieh PT et al. Detection of recurrent prostate carcinoma with anti-1-amino-3-18Ffluorocyclobutane- 1-carboxylic acid PET/CT and 111Incapromab pendetide SPECT/CT. Radiology 2011;259(3):852-861.
30. Dimitrakopoulou-Strauss A, Strauss LG. PET imaging of prostate cancer with 11C-acetate. J Nucl Med 2003;44(4):556-558.
31. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18] fluoro-D-glucose. Radiology 1996;199(3):751-756.
32. Schoder H, Herrmann K, Gonen M et al. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 2005;11(13):4761-4769.
33. Larson SM, Morris M, Gunther I et al. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 2004;45(3):366-373.
34. Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999;36(1):31-35.
35. Schuster DM, Votaw JR, Nieh PT et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 2007;48(1):56-63.
36. Oka S, Hattori R, Kurosaki F et al. A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. J Nucl Med 2007;48(1):46-55.
37. Okudaira H, Shikano N, Nishii R et al. Putative transport mechanism and intracellular fate of trans-1-amino-3-18Ffluorocyclobutanecarboxylic acid in human prostate cancer. J Nucl Med 2011;52(5):822-829.
38. Chade DC, Shariat SF, Cronin AM et al. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multiinstitutional collaboration. Eur Urol 2011;60(2):205-210.
39. Chade DC, Eastham J, Graefen M et al. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol 2012;61(5):961-971.
40. Williams SB, Hu JC. Salvage robotic assisted laparoscopic radical prostatectomy: indications and outcomes. World J Urol 2010 Nov 21.
41. Ward JF, Sebo TJ, Blute ML, Zincke H. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol 2005;173(4):1156-1160.
42. Gotto GT, Yunis LH, Vora K, Eastham JA, Scardino PT, Rabbani F. Impact of prior prostate radiation on complications after radical prostatectomy. J Urol 2010;184(1):136-142.
43. Masterson TA, Stephenson AJ, Scardino PT, Eastham JA. Recovery of erectile function after salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Urology 2005;66(3):623-626.
44. Stephenson AJ, Scardino PT, Bianco FJ Jr, DiBlasio CJ, Fearn PA, Eastham JA. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol 2004;172(6 Pt 1):2239-2243.
45. Finley DS, Belldegrun AS. Salvage cryotherapy for radiationrecurrent prostate cancer: outcomes and complications. Curr Urol Rep 2011;12(3):209-215.
46. Ismail M, Ahmed S, Kastner C, Davies J. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int 2007;100(4):760-764.
47. Spiess PE, Katz AE, Chin JL et al. A pretreatment nomogram predicting biochemical failure after salvage cryotherapy for locally recurrent prostate cancer. BJU Int 2010;106(2):194-198.
48. Spiess PE, Lee AK, Leibovici D, Wang X, Do KA, Pisters LL. Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy. Cancer 2006;107(2):275-280.
49. Caso JR, Tsivian M, Mouraviev V, Kimura M, Polascik TJ. Complications and postoperative events after cryosurgery for prostate cancer. BJU Int 2012;109(6):840-845.
50. Nguyen PL, Chen MH, D'Amico AV et al. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study. Cancer 2007;110(7):1485-1492.
51. Nguyen PL, Chen RC, Clark JA et al. Patient-reported quality of life after salvage brachytherapy for radio-recurrent prostate cancer: A prospective Phase II study. Brachytherapy 2009;8(4): 345-352.
52. Grado GL, Collins JM, Kriegshauser JS et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999;53(1):2-10.
53. Burri RJ, Stone NN, Unger P, Stock RG. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010; 77(5):1338-1344.
54. Lee B, Shinohara K, Weinberg V et al. Feasibility of high-doserate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 2007;67(4):1106-1112.
55. Ahmed HU, Cathcart P, Chalasani V et al. Whole-gland salvage high-intensity focused ultrasound therapy for localized prostate cancer recurrence after external beam radiation therapy. Cancer 2012118(12):3071-3078.
56. Gelet A, Chapelon JY, Poissonnier L et al. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 2004;63(4):625-629.
57. Master VA, Shinohara K, Carroll PR. Ferromagnetic thermal ablation of locally recurrent prostate cancer: prostate specific antigen results and immediate/intermediate morbidities. J Urol 2004;172(6 Pt 1):2197-2202.
58. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24(27):4448-4456.
59. Baxi S, Catton C. Practice patterns for post-prostatectomy hormonal therapy amongst Canadian radiation oncologists. Can J Urol 2010;17(6):5436-5441.
60. Crook JM, O'Callaghan CJ, Duncan G et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012;367(10):895-903.
61. Procopio G, Guadalupi V, Giganti MO et al. Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration. BJU Int 2011;108(2):223-227.
62. Keizman D, Huang P, Carducci MA, Eisenberger MA. Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression. Prostate 2012;72(4):461-467.
63. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-1512.
64. KantoffPW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-422.
65. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364(21):1995-2005.
66. Ryan CJ, Shah S, Efstathiou E et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 2011;17(14):4854-4861.
67. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376(9747):1147-1154.
68. Smith MR, Egerdie B, Hernandez Toriz N et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361(8):745-755.
69. Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377(9768):813-822.
70. Sartor AO, Helle SI, O'Sullivan JM et al. Radium-223 chloride impact on skeletal-related events in patients with castrationresistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA). J Clin Oncol 2012;30(18 (suppl)).
71. Scher HI, Beer TM, Higano CS et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375(9724):1437-1446.
72. Hori S, Butler E, McLoughlin J. Prostate cancer and diet: food for thought? BJU Int 2011;107(9):1348-1359.